Morgan Stanley’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $99.2M | Buy |
1,505,075
+239,774
| +19% | +$15.2M | 0.01% | 1449 |
|
|
2025
Q4 | $80.4M | Sell |
1,265,301
-255,885
| -17% | -$15.9M | ﹤0.01% | 1641 |
|
|
2025
Q3 | $83.6M | Buy |
1,521,186
+403,106
| +36% | +$16.6M | 0.01% | 1561 |
|
|
2025
Q2 | $36.9M | Buy |
1,118,080
+106,335
| +11% | +$3.7M | ﹤0.01% | 2199 |
|
|
2025
Q1 | $40.7M | Sell |
1,011,745
-241,243
| -19% | -$11.1M | ﹤0.01% | 2002 |
|
|
2024
Q4 | $58.9M | Buy |
1,252,988
+84,616
| +7% | +$4.39M | ﹤0.01% | 1690 |
|
|
2024
Q3 | $61.7M | Buy |
1,168,372
+62,698
| +6% | +$3.49M | ﹤0.01% | 1638 |
|
|
2024
Q2 | $59.9M | Buy |
1,105,674
+150,816
| +16% | +$9.1M | ﹤0.01% | 1584 |
|
|
2024
Q1 | $66.9M | Sell |
954,858
-3,848,306
| -80% | -$298M | 0.01% | 1495 |
|
|
2023
Q4 | $401M | Buy |
4,803,164
+3,750,958
| +356% | +$136M | 0.02% | 766 |
|
|
2023
Q3 | $31M | Buy |
1,052,206
+143,955
| +16% | +$4.79M | ﹤0.01% | 2020 |
|
|
2023
Q2 | $29.6M | Buy |
908,251
+96,007
| +12% | +$3.55M | ﹤0.01% | 2079 |
|
|
2023
Q1 | $28.6M | Sell |
812,244
-453,618
| -36% | -$18.5M | ﹤0.01% | 2057 |
|
|
2022
Q4 | $58M | Sell |
1,265,862
-144,504
| -10% | -$6.22M | 0.01% | 1380 |
|
|
2022
Q3 | $68.3M | Sell |
1,410,366
-89,739
| -6% | -$4.32M | 0.01% | 1116 |
|
|
2022
Q2 | $58.9M | Buy |
1,500,105
+329,286
| +28% | +$13.3M | 0.01% | 1259 |
|
|
2022
Q1 | $43.1M | Buy |
1,170,819
+299,157
| +34% | +$10.6M | 0.01% | 1401 |
|
|
2021
Q4 | $39.7M | Buy |
871,662
+30,738
| +4% | +$1.19M | ﹤0.01% | 1515 |
|
|
2021
Q3 | $30.1M | Sell |
840,924
-89,036
| -10% | -$2.62M | ﹤0.01% | 1693 |
|
|
2021
Q2 | $18.4M | Buy |
929,960
+226,743
| +32% | +$5.32M | ﹤0.01% | 2249 |
|
|
2021
Q1 | $16.4M | Sell |
703,217
-191,460
| -21% | -$4.09M | ﹤0.01% | 2134 |
|
|
2020
Q4 | $18.6M | Buy |
894,677
+53,600
| +6% | +$980K | ﹤0.01% | 1876 |
|
|
2020
Q3 | $18.2M | Buy |
841,077
+136,290
| +19% | +$3.19M | ﹤0.01% | 1552 |
|
|
2020
Q2 | $16.6M | Sell |
704,787
-256,868
| -27% | -$4.82M | ﹤0.01% | 1546 |
|
|
2020
Q1 | $11.3M | Sell |
961,655
-404,873
| -30% | -$5.17M | ﹤0.01% | 1670 |
|
|
2019
Q4 | $14.5M | Buy |
1,366,528
+1,090,420
| +395% | +$11.2M | ﹤0.01% | 1981 |
|
|
2019
Q3 | $3.14M | Sell |
276,108
-10,128
| -4% | -$127K | ﹤0.01% | 3370 |
|
|
2019
Q2 | $3.22M | Buy |
286,236
+196,786
| +220% | +$1.9M | ﹤0.01% | 3358 |
|
|
2019
Q1 | $724K | Sell |
89,450
-78,204
| -47% | -$575K | ﹤0.01% | 4325 |
|
|
2018
Q4 | $1.06M | Buy |
167,654
+23,310
| +16% | +$171K | ﹤0.01% | 4236 |
|
|
2018
Q3 | $1.42M | Sell |
144,344
-86,980
| -38% | -$698K | ﹤0.01% | 4264 |
|
|
2018
Q2 | $1.92M | Buy |
231,324
+90,265
| +64% | +$751K | ﹤0.01% | 4111 |
|
|
2018
Q1 | $1.01M | Sell |
141,059
-24,098
| -15% | -$207K | ﹤0.01% | 4531 |
|
|
2017
Q4 | $1.34M | Sell |
165,157
-63,015
| -28% | -$715K | ﹤0.01% | 4346 |
|
|
2017
Q3 | $3.31M | Sell |
228,172
-65,058
| -22% | -$889K | ﹤0.01% | 3391 |
|
|
2017
Q2 | $3.55M | Buy |
293,230
+10,919
| +4% | +$152K | ﹤0.01% | 3248 |
|
|
2017
Q1 | $3.63M | Buy |
282,311
+67,029
| +31% | +$783K | ﹤0.01% | 3214 |
|
|
2016
Q4 | $2.62M | Buy |
215,282
+161,644
| +301% | +$1.72M | ﹤0.01% | 3677 |
|
|
2016
Q3 | $493K | Buy |
53,638
+45,995
| +602% | +$480K | ﹤0.01% | 4531 |
|
|
2016
Q2 | $73K | Sell |
7,643
-1,848
| -19% | -$15.2K | ﹤0.01% | 5385 |
|
|
2016
Q1 | $67K | Sell |
9,491
-112,155
| -92% | -$819K | ﹤0.01% | 5493 |
|
|
2015
Q4 | $1.27M | Sell |
121,646
-727,832
| -86% | -$7.14M | ﹤0.01% | 3875 |
|
|
2015
Q3 | $5.68M | Buy |
849,478
+474,290
| +126% | +$3.24M | ﹤0.01% | 2541 |
|
|
2015
Q2 | $2.52M | Buy |
375,188
+16,491
| +5% | +$108K | ﹤0.01% | 3408 |
|
|
2015
Q1 | $2.43M | Buy |
358,697
+254,683
| +245% | +$1.9M | ﹤0.01% | 3413 |
|
|
2014
Q4 | $833K | Sell |
104,014
-158,136
| -60% | -$679K | ﹤0.01% | 4298 |
|
|
2014
Q3 | $923K | Sell |
262,150
-176,629
| -40% | -$742K | ﹤0.01% | 4101 |
|
|
2014
Q2 | $2.1M | Buy |
438,779
+202,204
| +85% | +$1.23M | ﹤0.01% | 3447 |
|
|
2014
Q1 | $2.25M | Buy |
236,575
+65,913
| +39% | +$596K | ﹤0.01% | 3313 |
|
|
2013
Q4 | $1.11M | Sell |
170,662
-122,059
| -42% | -$802K | ﹤0.01% | 3857 |
|
|
2013
Q3 | $2.22M | Buy |
+292,721
| New | +$3.14M | ﹤0.01% | 3136 |
|
Other funds holding CYTK
VPM
VCM
ACA
Morgan Stanley's CYTK Position: Q1 2026 in Review
Morgan Stanley increased its Cytokinetics (CYTK) stake by 19% in Q1 2026, buying an estimated $15.2M and bringing the position to 1,505,075 shares worth $99.2M. The position accounts for 0.01% of the portfolio, ranked #1449.
Morgan Stanley first reported a position in CYTK in Q3 2013 and has held it in 51 quarters since. The position peaked at $401M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Morgan Stanley held 1,505,075 shares of Cytokinetics worth $99.2M as of Q1 2026.
- Morgan Stanley bought 239,774 Cytokinetics shares in Q1 2026, an estimated $15.2M.
- Cytokinetics made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1449 holding.
- Morgan Stanley first reported a position in Cytokinetics in Q3 2013 and has held it in 51 quarters since.
- Morgan Stanley's Cytokinetics position peaked at $401M in Q4 2023.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.